Research programme: platelet aggregation inhibitors - Astellas/Alexion AstraZeneca Rare Disease
Alternative Names: Platelet adhesion inhibitors research programme - Astellas/Alexion AstraZeneca Rare DiseaseLatest Information Update: 14 Feb 2022
At a glance
- Originator Astellas Pharma
- Class
- Mechanism of Action Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Vascular disorders
Most Recent Events
- 14 Jun 2005 Preclinical trials in Vascular disorders in USA (unspecified route)